SAB Biotherapeutics (SABS) to Release Earnings on Thursday

SAB Biotherapeutics (NASDAQ:SABS) will likely be posting its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect SAB Biotherapeutics to post earnings of ($1.16) per share and revenue of $0.12 million for the quarter.

SAB Biotherapeutics Stock Performance

Shares of NASDAQ:SABS opened at $1.62 on Thursday. SAB Biotherapeutics has a 1-year low of $1.45 and a 1-year high of $5.01. The firm’s 50 day simple moving average is $2.32 and its two-hundred day simple moving average is $2.90. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09.

Analysts Set New Price Targets

SABS has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a report on Wednesday, January 29th. Chardan Capital restated a “buy” rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a research report on Wednesday, January 29th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SAB Biotherapeutics presently has a consensus rating of “Buy” and a consensus price target of $12.40.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.